Michael Vincent Meluzio Sells 5,628 Shares of Cue Biopharma (NASDAQ:CUE) Stock

Cue Biopharma, Inc. (NASDAQ:CUE) VP Michael Vincent Meluzio sold 5,628 shares of the stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $30.09, for a total transaction of $169,346.52. Following the transaction, the vice president owned 48,961 shares in the company, valued at $1,473,236.49. This trade represents a 10.31% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Cue Biopharma Trading Down 7.0%

NASDAQ:CUE opened at $25.70 on Wednesday. The firm has a market capitalization of $107.94 million, a PE ratio of -0.95 and a beta of 2.47. Cue Biopharma, Inc. has a 52 week low of $4.97 and a 52 week high of $45.50. The stock has a 50 day moving average of $29.37 and a 200-day moving average of $141.55.

Cue Biopharma (NASDAQ:CUE) last announced its quarterly earnings results on Friday, August 14th. The company reported ($24.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.69) by ($22.45). The business had revenue of $7.88 million for the quarter, compared to analyst estimates of $3.00 million. Cue Biopharma had a negative return on equity of 482.58% and a negative net margin of 435.83%.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Northwestern Mutual Wealth Management Co. bought a new stake in shares of Cue Biopharma in the 2nd quarter worth approximately $83,000. Bank of America Corp DE acquired a new position in Cue Biopharma in the second quarter worth approximately $219,000. Seven Fleet Capital Management LP acquired a new position in Cue Biopharma in the second quarter worth approximately $337,755,000. Persistent Asset Partners Ltd bought a new position in shares of Cue Biopharma in the second quarter valued at $389,000. Finally, Texas Capital Bank Wealth Management Services Inc acquired a new stake in shares of Cue Biopharma during the 2nd quarter valued at $722,000. Institutional investors own 35.04% of the company’s stock.

Analyst Ratings Changes

Several research firms have commented on CUE. Weiss Ratings reissued a “sell (d-)” rating on shares of Cue Biopharma in a research note on Thursday, August 13th. Wall Street Zen cut shares of Cue Biopharma from a “buy” rating to a “hold” rating in a report on Saturday. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has an average rating of “Sell”.

About Cue Biopharma

Cue Biopharma is a clinical‐stage biotechnology company focused on the development of next‐generation immunotherapies for cancer and infectious diseases. The company’s proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen‐specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early‐stage clinical studies.